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Abstract
Background: Aspirin has been considered to be beneficial in preventing cardiovascular diseases and cancer.
Several pharmaco-epidemiology cohort studies have shown protective effects of aspirin on diseases using various
statistical methods, with the Cox regression model being the most commonly used approach. However, there are
some inherent limitations to the conventional Cox regression approach such as guarantee-time bias, resulting in an
overestimation of the drug effect. To overcome such limitations, alternative approaches, such as the time-
dependent Cox model and landmark methods have been proposed. This study aimed to compare the performance
of three methods: Cox regression, time-dependent Cox model and landmark method with different landmark times
in order to address the problem of guarantee-time bias.
Methods: Through statistical modeling and simulation studies, the performance of the above three methods were
assessed in terms of type I error, bias, power, and mean squared error (MSE). In addition, the three statistical
approaches were applied to a real data example from the Korean National Health Insurance Database. Effect of
cumulative rosiglitazone dose on the risk of hepatocellular carcinoma was used as an example for illustration.
Results: In the simulated data, time-dependent Cox regression outperformed the landmark method in terms of
bias and mean squared error but the type I error rates were similar. The results from real-data example showed the
same patterns as the simulation findings.
Conclusions: While both time-dependent Cox regression model and landmark analysis are useful in resolving the
problem of guarantee-time bias, time-dependent Cox regression is the most appropriate method for analyzing
cumulative dose effects in pharmaco-epidemiological studies.
Keywords: Cox regression, Guarantee-time bias, Landmark method, Time-dependent Cox regression
Background
Extensive studies have elaborated and documented protect-
ive effect of aspirin for the primary prevention of cardiovas-
cular diseases, including myocardial infarction (MI), stroke,
coronary artery disease (CAD) [1–6]. Distinct from other
non-steroidal anti-inflammatory drugs (NSAIDs), aspirin
has the capacity to irreversibly inhibit cyclooxygenase
(COX) and suppress thromboxane production. Findings of
experimental studies have suggested that COX-2 suppres-
sion [7–9] or anti-platelet effect of aspirin [10, 11] could
interact with cancer cells and play a significant role in
blocking tumor angiogenesis, invasiveness and metastatic
potential. Accordingly, several observational studies have re-
ported an inverse association between aspirin use and can-
cer incidence or mortality. However, the results have been
inconsistent and controversy still remains regarding its anti-
cancer effects [12–15], in part due to variations in study de-
signs and statistical methods for analyzing the effectiveness
of aspirin. For example, Fraser et al. [16] conducted a
population-based study of breast cancer patients in Scotland,
in which Cox’s proportional hazard models was used to
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assess the relationship between aspirin use and survival. The
authors found significantly reduced all-cause (HR = 0.53,
95% CI = 0.45 to 0.63) and breast cancer-specific mortality
(HR = 0.42, 95% CI = 0.31 to 0.55) among participants who
consumed aspirin following a diagnosis of breast cancer.
Similarly, using Cox proportional hazards modeling, Jacobs
et al. [17] reported that total cancer incidence is significantly
lower among regular long-term aspirin users (RR = 0.84,
95% CI = 0.76 to 0.93). In contrast, a study by McMenamin
and colleagues [18] found a non-significant decrease in the
risk of lung cancer-specific mortality (p = 0.5975) with as-
pirin use. In this study, the authors used a time-dependent
Cox model whereby low-dose aspirin usage was treated as
time-varying covariate, with users not considered to be ex-
posed until after a lag of six months following initial prescrip-
tion. Further, Cardwell et al. [19], in their conditional logistic
regression analysis of nested case-control data, also found no
evidence for protective effects of low-dose aspirin usage
against colon cancer-specific mortality (OR = 1.06; 95%
CI = 0.92 to 1.24).
The above-mentioned studies of aspirin use show that
when evaluating drug effects, results are often confounded
by time-related biases that tend to exaggerate the protective
effects, even when the drug has no or little effect [20]. Time-
related biases can be further categorized into guarantee-time
bias (also known as immortal time bias or time-dependent
bias), time-window bias, or time-lag bias. For the purpose of
this paper, we focus on guarantee-time bias, which is fre-
quently encountered in time-to-event analyses evaluating
drug effects. Guarantee-time bias refers to bias arising from
incorrect handling of the time from the beginning of follow-
up to the first treatment exposure [21]. The bias occurs if
treated patients are assumed to have already been treated
from time of cohort entry. For example, in a study of patients
with heart disease, heart transplant is a time-varying treat-
ment. While some patients may receive a transplant at the
start of follow-up, others may undergo transplant long after
the beginning of follow-up or die before undergoing the
transplant. Failure to account for time-varying feature of the
treatment can result in biased estimation of the treatment
effect, in this case, in favor of the treatment group [22].
This study aimed to evaluate the extent of guarantee-
time bias in estimation of drug effects on disease out-
comes. We conducted simulation studies in which time-
fixed, time-dependent Cox model, and landmark analysis
were compared for handling guarantee-time bias. For il-
lustrative purposes, effect of cumulative rosiglitazone
dose on the risk of hepatocellular carcinoma was investi-
gated using the Korean National Health Insurance Data.
Method
Guarantee-Time bias
Guarantee-time bias in cohort studies can distort the re-
sults in favor of the treatment group, depending on the type
of event (if it benefits the patient or not) [21, 23, 24]. In de-
tail, consider this study as a cohort study and the situation
where drug effect and event occurrence are independent.
Event is defined as the disease of interest. Define the ran-
dom variables W and T0 as the time to initiation of drug
usage and time to occurrence of event. The binary random
variable Z is defined to be Z = I[W ≤T0], which represents
drug usage. The random variables T0 and T1 are defined as
the time to event conditional on Z = 0 or 1 respectively, i.e.
T = (1 −Z)T0 +ZT1. As shown in Fig. 1, the person whose
value of T0 is smaller than W is allocated to the non-user
group (person #1). Otherwise, individuals are allocated to
the drug-user group, according to cumulative drug expos-
ure (persons #2 to 4). In other words, to have received the
treatment implies that the subject survived or was event-
free, up to the initiation of drug use. As regards drug-user
groups, the longer the survival times, the higher the prob-
ability of belonging to the high-dose group. This is the
guarantee-time bias phenomenon, i.e. subjects must have
lived long enough to receive the treatment and consume
large amounts of drug.
Statistical modeling for Guarantee-Time bias
Our statistical modeling closely follows the paper by Nam
and Zelen [25]. For convenience, we consider the situation
where the drug usage is binary. The probability density
functions of W , T0 , T1 will be denoted by g(w) , q0(t)
and q1(t) respectively. The survival functions will be de-
noted by G(w) = Pr[W >w] , Q0(t) = Pr[T0 > t] and Q1(t) =
Pr[T1 > t]. Note that by definition Z = 1 if the time for drug
usage is observed. If the drug usage does not cause a
change in the survival function, the conditional density
function of non-user group f(t| z = 0) and drug-user group
f(t| z = 1) would be the same.
Under the hypothesis that q0(t) = q1(t), if we simply
compare the survival functions of the two groups accord-
ing to the drug usage, the two groups of conditional dens-
ity functions are not equal to f(t| z = 0) ≠ f(t| z = 1), as it
has been proven in the paper by Nam and Zelen [25].
Therefore, it is not appropriate to simply compare the sur-
vival functions of two groups according to drug usage.
Landmark method
In the landmark method, selected landmark time τ0 is
set, and binary random variable Z(τ0) is defined as Z(τ0)
= I(W < τ0| T > τ0). The conditional density functions for
Z(τ0) can be computed as follows [25]:
f tjZ τ0ð Þ ¼ 0ð Þ ¼ q1 tð Þ A tð Þ−A τ0ð Þ½  þ G tð Þq0 tð ÞR∞
τ0
q1 xð Þ A xð Þ−A τ0ð Þ½  þ G xð Þq0 xð Þf gdx
for t > τ0
f tjZ τ0ð Þ ¼ 1ð Þ ¼ q1 tð ÞQ1 τ0ð Þ
for t > τ0
where A(t) = 1 −G(t).
Cho et al. BMC Medical Research Methodology  (2017) 17:126 Page 2 of 7
Hence if q0(t) = q1(t), it can be seen that the two func-
tions are the same as
f tjZ τ0ð Þ ¼ 0ð Þ ¼ f tjZ τ0ð Þ ¼ 1ð Þ
¼ q0 tð Þ=Q0 τ0ð Þ for t > τ0:
As a result, it is possible to make a valid comparison
of two survival functions between the drug-user and
non-user groups using the landmark method. In this
study, landmark analysis was conducted using time-fixed
Cox regression with drug exposure status defined prior
to landmark time. One thing to mention in the land-
mark method is that it is very important to carefully se-
lect the landmark time.
Time-dependent Cox regression model
In a time-dependent Cox regression model, a time-
dependent covariate in the model tracks whether the clas-
sifying event has occurred during the estimation process
[23]. This method eliminates guarantee-time bias by using
drug usage as a time-dependent covariate; subjects are
classified as unexposed until the start of drug usage and
exposed thereafter [26–28]. The time-dependent Cox re-
gression model has the advantage of using all study
follow-up data since it starts analysis at the time of cohort
entry. By including all data, this method has increased
statistical power over the landmark method [29].
Simulation setting
We conducted extensive simulations to compare the
performance of our three methods, Cox regression,
time-dependent Cox regression and landmark method,
in terms of empirical type I error and power. We used
a discrete-time survival model to describe the effect of
cumulative drug dose on the outcome using three in-
dicator variables Z1(t) , Z2(t) , Z3(t) which represent
low, moderate and high-drug dose groups. We set N
as total sample size and d as the number of drug-
users. Among N subjects, d subjects consumed drug
for different durations and the dosage was fixed at a
constant dose of 0.5 per unit of time. We assumed that
drug is taken continuously without interruption until
the end of the study or event.
We divided the total observation period (10-year)
into ten intervals as needed for the discrete-time sur-
vival model. The overall simulation setting is repre-
sented in Fig. 2. We assumed that the drug user rate
is 5%. First, we randomly assigned time to initiation
of drug use between 0 and 10 for each drug-user.
Using these initiation times, we calculated cumulative
dose at each time t and categorized each subject into
four groups: non-user group and low(Z1(t) = 1), mod-
erate(Z2(t) = 1), high-dose(Z3(t) = 1) groups. At each
discrete time point, the probability of disease occur-
rence at time t is as follows:
Fig. 1 Guarantee-Time Bias Considering four people, time to initiation of drug use wi and a time to event ti were randomly generated for each
person. The person whose value of T0 is smaller than W is allocated to the non-user group (person #1). Otherwise, individuals are allocated to the
drug-user group, according to cumulative drug exposure (persons #2 to 4)
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P tð Þ ¼ exp β0 þ β1Z1 tð Þ þ β2Z2 tð Þ þ β3Z3 tð Þ
 
1þ exp β0 þ β1Z1 tð Þ þ β2Z2 tð Þ þ β3Z3 tð Þ
 
If the event occurred within the observation period, sur-
vival time is the point of event occurrence. On the other
hand, if the event did not occur, survival time is equal to
10 years and censored. For the landmark analysis, we con-
sidered subjects whose starting point of drug intake is be-
fore landmark time as drug-users, and otherwise non-
user. We used 5 and 7 as landmark times, respectively.
Subjects who died or who were censored before the land-
mark time were excluded from the analysis.
Simulations were performed under two different scenar-
ios. In the first scenario, type I error rates for each of the
statistical methods were evaluated under the null hypothesis,
whereby β1, β2 and β3 values were set to zero to represent a
case of no significant protective effect of drug on disease
outcome. For the power comparisons in scenario 2, we sim-
ulated data from the alternative hypothesis (i.e. cumulative
drug dose is associated with disease outcome) for each of
the three β0 values denoting disease incidence: log(0.015),
log(5∗0.015) , and log(10∗0.015). For each simulation setting,
1000 replication datasets were generated. All simulations
were performed using the R statistical software [30].
Results
Simulation results
The empirical type I errors of three methods under the
null hypothesis of no association between cumulative
drug dose and disease are illustrated in Table 1. Each
value represents the total number of cases out of 1000
replications for which the null hypothesis is incorrectly
rejected. As expected, Cox regression model with fixed
covariate values tended to produce inflated type I error
rates, especially in the moderate and high dose groups.
Time-dependent Cox regression and landmark method,
on the other hand, displayed well-controlled type I error
Fig. 2 Description of Simulation setting
Table 1 Estimated Empirical type I error of Cox regression,
Time-dependent Cox regression and Landmark methods on
simulated data under the null hypothesis that aspirin is not
significantly related to cancer
β0 Cumulative
dose
Cox
regression
Time-
dependent
Cox
regression
Landmark analyses
τ = 5 τ = 7
log(0.015) Low 214 58 56 57
Moderate 1000 52 42 45
High 1000 43 55 47
log(5∗0.015) Low 723 47 56 66
Moderate 1000 50 40 44
High 1000 47 46 46
log(10∗0.015) Low 957 52 62 52
Moderate 1000 59 50 48
High 1000 46 46 44
Each value represents the number of cases out of 1000 replications for which
the null hypothesis is incorrectly rejected
Two values of landmark time (τ) are used, 5 and 7. β0 values represent disease
incidence rate
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rates; nearly all values remained close to the nominal
level of significance of 0.05, regardless of the degree of
disease incidence.
The power estimates for the alternative hypothesis are
displayed in Table 2. Statistical power of the time-
dependent Cox regression approach was higher than that
of landmark analyses in the high-dose group. In the case of
moderate and low-dose groups, the landmark method
using landmark time 5 demonstrated higher statistical
power compared to the time-dependent Cox regression.
This is attributed to the fact that there was extremely small
number of cases for the high-dose group, compared with
the moderate group.
Table 3 summarizes the bias and mean squared errors
(MSE) of hazard ratios for estimation of the association
between cumulative drug dose and outcome. Time-
dependent Cox regression had much lower bias than the
landmark method and generally showed smaller MSE
values compared with the other methods. For instance, for
the low-dose group, when the β0 value was log(0.015), the
bias of the time-dependent Cox regression model was
0.0009, while the bias of the landmark analyses were
0.0673 and 0.0416 for τ = 5 and τ = 7, respectively.
Real data example
We applied our simulation findings to a real data from the
Korean National Health Insurance Database (NHID). The
sample was followed for 12 years from 2002 to 2013. The
event of interest was incidence of hepatocellular carcin-
oma (HCC). Among 47,738 patients with incident dia-
betes, 203 hepatocellular carcinoma cases were identified.
Full details of the study design have been described else-
where [31, 32]. In the current study, total prescribed doses
of rosiglitazone were calculated at each year and summed
to produce cumulative doses of follow-up years. Discrete-
time survival analysis was used to take into account of the
intermittent administration of rosiglitazone and the vary-
ing dosage between patients. Based on cumulative dose of
rosiglitazone use during the study period, drug users were
categorized into low (<1350 mg), moderate (1350–
4499 mg), high groups (≥4500 mg). In the landmark ana-
lysis, sixth year was chosen as a landmark time since the
number of incident HCC was balanced at that time point.
Data analysis was carried out using the SAS statistical soft-
ware version 9.4 [33].
Results based on the NHID data are illustrated in
Table 4. In the Cox regression, the risk of HCC inci-
dence was lowest among subjects exposed to high cu-
mulative doses of rosiglitazone (HR = 0.443, 95%
CI = 0.218 to 0.899). However, the protective pattern
of dose-response relationship and effect sizes were
Table 2 Power comparisons of Cox regression, Time-dependent
Cox regression and Landmark methods on simulated data under
the alternative hypothesis that cumulative drug dose is significantly
related to disease outcome
β0 Cumulative
dose
Cox
regression
Time-
dependent
Cox
regression
Landmark analyses
τ = 5 τ = 7
log(0.015) Low 214 58 119 74
Moderate 1000 109 348 181
High 1000 627 186 396
log(5∗0.015) Low 723 47 289 103
Moderate 1000 296 792 471
High 1000 977 452 827
log(10∗0.015) Low 957 52 288 94
Moderate 1000 322 836 523
High 1000 989 538 888
β0 values represent disease incidence rate; τ= Landmark time
Table 3 Bias and MSE of Hazard ratio for estimation of the association between cumulative drug dose and outcome
β0 Cumulative dose Cox regression Time-dependent
Cox regression
Landmark analyses
τ = 5 τ = 7
Bias MSE Bias MSE Bias MSE Bias MSE
log(0.015) Low 0.0732 0.0035 0.0009 0.0041 0.0673 0.0062 0.0416 0.0105
Moderate 0.2735 0.0019 0.0005 0.0043 0.0641 0.0043 0.0469 0.0068
High 0.6210 0.0004 0.0419 0.0034 0.0437 0.0174 0.0429 0.0061
log(5∗0.015) Low 0.0822 0.0009 0.0007 0.0012 0.0614 0.0020 0.0352 0.0034
Moderate 0.3002 0.0004 −0.0024 0.0012 0.0585 0.0013 0.0455 0.0023
High 0.6263 0.0001 0.0392 0.0011 0.0377 0.0048 0.0366 0.0019
log(10∗0.015) Low 0.0944 0.0006 0.0011 0.0008 0.0565 0.0016 0.0300 0.0029
Moderate 0.3349 0.0002 −0.0032 0.0009 0.0524 0.0011 0.0461 0.0020
High 0.6331 0.0001 0.0360 0.0009 0.0360 0.0038 0.0338 0.0016
β0 values represent disease incidence rate, MSE Mean squared error, τ Landmark time
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considerably attenuated in the time-dependent Cox
regression and landmark analysis.
Discussion
In this study, we examined the phenomenon of guarantee-
time bias through statistical modeling and simulation
study. Specifically, our simulation study assessed the per-
formance of three methods, namely Cox regression, time-
dependent Cox regression and landmark method based
on time-fixed Cox regression. These methods depend
upon the proportional hazard assumption. According to
our simulation results, time-fixed Cox regression was
shown to be vulnerable to guarantee-time bias [20, 22].
Pharmaco-epidemiological studies typically involve the
use of time-varying exposures, such as cumulative dose.
Hence, under such situations, applying the time-fixed Cox
regression approach can induce bias due to model misspe-
cification. Our results are in accordance with results previ-
ously reported by Mi et al. [29]. However, unlike previous
studies, we performed a simulation by including cumula-
tive dose groups as exposures.
Landmark analysis has been suggested in previous studies
as a simplified alternative to time-dependent Cox regres-
sion for elimination of guarantee-time bias in time-to-event
data. In our simulation, landmark method was comparable
to the time-dependent Cox regression method in terms of
type I error. But landmark analysis tended to slightly in-
crease MSE. One possible explanation for these results
could be the sample size. For landmark analysis to produce
efficient estimates, it is imperative that optimal landmark
time is specified. As illustrated by our results, if the land-
mark point is too early, there is a greater possibility of im-
balanced observations among treatment groups. On the
other hand, if the landmark point is too late, a significant
proportion of events may be omitted, giving rise to insuffi-
cient number of cases to achieve adequate power. Thus, it
is important that landmark studies are designed with suffi-
cient number of participants to maintain adequate statis-
tical power. Additionally, the landmark method will
produce estimates with minimal bias conditional upon the
treatment being evenly distributed across the follow-up
[29]. Recently, the use of landmark super models, a pooled
summary analysis of several landmarks, has been advocated
to remedy the problem of low statistical power related to
the landmark method [34, 35]. Further studies are war-
ranted to compare the performance of landmark super
models with the time-dependent Cox model.
Nevertheless, the landmark approach has several ad-
vantages over the time-dependent Cox regression model.
Most notably, this method has the advantage of compu-
tational simplicity because drug use is defined as a time-
fixed covariate by using landmark time. Thus, one can
visualize the survival curve of drug users using the
Kaplan-Meier method. But, unconditional Kaplan-Meier
estimates of time-varying status of drug users are un-
stable because the number of drug users can be quite
small at early time point [36].
Conclusions
In conclusion, to avoid guarantee-time bias in observa-
tional studies of drug effects, we recommend incorporat-
ing time-dependent exposure status in the analysis. While
both time-dependent Cox regression model and landmark
analysis were found to be useful in resolving the problem
of guarantee-time bias, time-dependent Cox regression
was the most appropriate method for analyzing cumula-
tive and long-term drug exposure. We recommend the
time-dependent Cox regression for estimating hazard ra-
tios of cumulative doses. Alternatively, due to its graphical
capabilities, the landmark method may be a suitable alter-
native for visualizing survival curves for treatment groups.
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